Document is current
Any future updates will be listed below
-
Authors
Luciano-Mateo, Fedra
Moreno-Caceres, Joaquim https://orcid.org/0000-0002-4166-9419
Hernández-Madrigal, Miguel https://orcid.org/0000-0003-2834-1723
Püschel, Franziska
Collado-Rodriguez, Lidia
Favaro, Francesca https://orcid.org/0000-0002-4184-140X
Hijazo-Pechero, Sara
Cruz-Rodríguez, Mabel
Jiménez-Hernández, Felipe
Villagrasa-Araya, Verónica https://orcid.org/0000-0002-6843-4476
Figueras-Duch, Nil https://orcid.org/0000-0003-0404-8485
Redondo-Pedraza, Jaime
Palau-Gallinat, Didac https://orcid.org/0009-0006-9290-1114
Plans-Marin, Silvia https://orcid.org/0000-0002-7661-4899
Figueras, Agnés
Fuentes Varela, Pedro https://orcid.org/0000-0001-8471-0197
de Benito-Gómez, Lidia
Gentilella, Antonio https://orcid.org/0000-0002-6830-2086
Perales, José Carlos https://orcid.org/0000-0001-7363-2226
Solé, Xavier https://orcid.org/0000-0002-2197-3325
Méndez-Lucas, Andrés https://orcid.org/0000-0002-0725-4375
Viñals, Francesc https://orcid.org/0000-0002-9918-6751
Nadal, Ernest https://orcid.org/0000-0002-9674-5554
Muñoz-Pinedo, Cristina https://orcid.org/0000-0002-9120-664X
- License Information
-
More Information
Article History
Received: 15 May 2022
Accepted: 28 November 2025
First Online: 30 January 2026
Competing interests
: E.N. declares research funding from Roche, Pfizer, Merck Serono and Bristol Myers Squibb; advisory board and consulting roles at Amgen, Apollomics, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Genmab, Johnson and Johnson, Lilly, Merck Sharp and Dohme (MSD), Merck Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi and Takeda; honoraria for lectures from Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Illumina, Johnson and Johnson, Lilly, MSD, Merck Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi and Takeda; and travel support from Roche, Takeda, Johnson and Johnson and MSD. C.M.-P. declares honorarium for lecture fees from Bristol Myers Squibb. The other authors declare no competing interests.
